GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
885
c/survodutide·posted 5 months ago by u/employer_carveout

three years of hepatic fat threads, summarised so you do not have to read them

Trial Data Well Actually ×2

Been lurking in c/t2dglp1 for about 4 months and finally have something worth posting.

Short version: week 44, 2.4mg, and hepatic fat is the bit I still cannot get a straight answer on. I have read the wiki, I have read the last 9 threads, and the answers split roughly down the middle.

What I actually want to know is whether the people saying it does not matter have measured it, or whether it is just repeated confidently. Happy to be told I am overthinking this — I probably am — but I would rather overthink it now than at week 38.

1,170 up / 285 down80% upvoted56 commentsid 1vtwng24 Feb 2026

56 comments

24 in this archive, depth 5

best — the order this archive was captured in

u/tomas_lokken121 points·5 months ago

glucagon co-agonism has a different safety story

replysharereportpermalink
u/employer_carveoutOP86 points·5 months ago

Disagree. What you are describing is consistent with biopsy, not with what you concluded.

replysharereportpermalink
u/employer_carveoutOP47 points·5 months ago

The injection-site soreness was genuinely awful for three weeks and then simply stopped. I know that is not useful information, but it is what happened.

replysharereportpermalink
u/lina_ndiaye84 points·5 months ago

Yeah, glucagon co-agonism is genuinely different.

replysharereportpermalink
u/quant_not_qual50 points·5 months ago

Week 38 for me and the honest summary is: 4kg down, muscle cramps manageable, and I have thought about food maybe four times today.

replysharereportpermalink
u/kaia_cabrera41 points·5 months ago

Hepatic fat or MASH or what?

replysharereportpermalink
u/tired_ledger_ftw46 points·5 months ago

glucagon co-agonism has a different safety story

replysharereportpermalink
u/runa_pires32 points·5 months ago

Disagree. What you are describing is consistent with MASH, not with what you concluded.

replysharereportpermalink
u/thermal_mass_tom22 points·5 months ago

the GLP-1/glucagon dual is hepatic fat, different from GIP/GLP-1

replysharereportpermalink
u/employer_carveoutOP12 points·5 months ago

My version of this: I was so worried about the injection that I put it off for eleven days. The injection is the easiest part.

replysharereportpermalink
u/mod_cold_roommod · c/coldchain18 points·5 months ago

Not convinced. The evidence does not support that reading.

replysharereportpermalink
u/cato_batista15 points·5 months ago

This is correct. Do not generalise from tirzepatide.

replysharereportpermalink
u/vikram_mbeki10 points·5 months ago

not approved, descriptive posts only

replysharereportpermalink
u/neha_rahimi0 points·5 months ago

not approved, descriptive posts only

Disagree on that part. 96.8% and 96.2% on the same vial is normal.

replysharereportpermalink
u/isabela_nilsen14 points·5 months ago

Phase 12 or 9?

replysharereportpermalink
u/elin_tamm37 points·5 months ago·edited

Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.

replysharereportpermalink
u/trialwatch_theoMOD22 points·5 months ago

Flair changed to match the content. Read the sidebar before posting next time and we are square.

replysharereportpermalink
u/camila_marchand23 points·5 months ago

Strongly agree. The safety story is separate.

replysharereportpermalink
u/crosspost_bot_no16 points·5 months ago
post the spreadsheet
replysharereportpermalink
u/samir_falk11 points·5 months ago

the safety profile is not just tirzepatide amplified

replysharereportpermalink
u/isabela_nilsen6 points·5 months ago

Yeah, glucagon co-agonism is genuinely different.

replysharereportpermalink
u/zeynep_villalobos-6 points·5 months ago

glucagon co-agonism has a different safety story

replysharereportpermalink
u/rafael_sjoberg1 point·5 months ago

rodent dual agonist is investigation only

replysharereportpermalink
u/renzo_yildiz1 point·5 months ago·edited

glucagon co-agonism has a different safety story

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →